Clinical trial · Observational
Cancer Patients Treated With Immunotherapy in Intensive Care Unit
Characteristics and Care of Solid Tumor Patients Treated With Immunotherapy Admitted in Intensive Care Unit.
NCT03357861CI-TRIAL-00054659IMMUNO-REAcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This work aims to describe the characteristics and methods of management of patients suffering from a solid tumor treated with immunotherapy admitted to intensive care.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Critical Illness | — | UNRESOLVED | — |
| Immunotherapy | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To evaluate the imputability of immunotherapy in the ICU admission reason for lung cancer patients treated by immunotherapy.
- timeFrame
- At ICU discharge (maximum 30 days)
- description
- Description of ICU admission reason (immunotherapy toxicity versus other) for lung cancer patients treated by immunotherapy
Secondary outcomes (3)
- measure
- Description of the immunosuppressive treatments prescribed during the stay in intensive care for the patient's care.
- timeFrame
- At ICU discharge (maximum 30 days)
- description
- immunosuppressive treatments in intensive care unit
- measure
- Description of ICU survival
- timeFrame
- At ICU discharge (maximum 60 days)
- description
- ICU survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * \> or = 18 years old; * with a solid tumor; * Treatment with anti-CTLA4 and / or anti-PD-1 / PDL-1 still in progress or up to 6 months after stopping; * Admitted to resuscitation or continuous care in an unprogrammed way, whatever the reason. Exclusion Criteria: * Minors; * Pregnant or lactating woman; * Admission after surgery of a scheduled surgery or for the security of procedure; * Anti-CTLA4 and / or anti-PD-1 / PDL-1 treatment stopped for more than 6 months; * Subject under guardianship or deprivation of liberty; * Refusal of consent; * No affiliation to a health insurance scheme.
References
Publications (0)
Data not yet available
No reference posted for this study.